Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04609280 · ClinicalTrials.gov registry record · Phase 2
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
A Phase 2 study of Head and Neck Cancer and Oropharynx Cancer, sponsored by University of Maryland, Baltimore.
- Active
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 6
- Study locations
NCT04609280 is a Phase 2 study of Head and Neck Cancer and Oropharynx Cancer that is active but no longer recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 52 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (80% lower). The trial reports 6 study locations across 1 state.
The verdict
NCT04609280, a Phase 2 study of Head and Neck Cancer and Oropharynx Cancer, is active but no longer recruiting, sponsored by University of Maryland, Baltimore.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a phase II, non-randomized, therapeutic trial with the primary objective to determine the efficacy of reduced contralateral (C/L) elective nodal treatment volumes in preventing C/L recurrences at 2 years in patients with p16 positive oropharyngeal squamous cell carcinoma undergoing definitive or adjuvant RT.
Conditions Studied
Interventions
- RADIATION Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)
Study Locations (6)
Maryland
- Maryland Proton Treatment Center - Baltimore
- UMMC - Baltimore
- University of Maryland Greenebaum Cancer Center - Baltimore
- Upper Chesapeake Health - Bel Air
- Central Maryland Radiation Oncology - Columbia
- Baltimore Washington Medical Center - Glen Burnie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04609280
The ClinicalTrials.gov registry entry for NCT04609280 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (80% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT) is the first listed.
NCT04609280 reports 6 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04609280 about?
NCT04609280 is a clinical study titled "Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)". This is a phase II, non-randomized, therapeutic trial with the primary objective to determine the efficacy of reduced contralateral (C/L) elective nodal treatment volumes in preventing C/L recurrences at 2 years in patients with p16 positive oropharyngeal squamous cell carcinoma undergoing definitiv...
What is the current status of trial NCT04609280?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2021-03-01. Estimated completion is 2027-12.
What conditions does trial NCT04609280 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Oropharynx Cancer, Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04609280?
The interventions under investigation include: Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT) (RADIATION).
Who is sponsoring clinical trial NCT04609280?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04609280 being conducted?
This trial has 6 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.